Hindustan Laboratories receives SEBI observations for its proposed IPO

• The offer, with a total issue size of up to 1,41,00,000 equity shares of face value Rs10 each, comprises a fresh issue of up to 50,00,000 equity shares and an offer for sale (OFS) of up to 91,00,000 equity shares.
• Rajesh Vasantray Doshi is the promoter selling shareholder and will offload up to 91,00,000 shares under the OFS.
• The company supplied its products across India to 27 states and Union Territories during the six months ended September 30, 2025, and to 27 states and Union Territories during Fiscal 2025, as per the DRHP.
• During his career, he has gained extensive exposure to equity research, market analysis, and financial data interpretation, strengthening his expertise across asset classes and market cycles.

Article Brief

Hindustan Laboratories Limited has received SEBI observations for its proposed IPO of up to 1,41,00,000 equity shares. The funds will support working capital and corporate needs. The company primarily manufactures generic medicines for government institutions.

Regulatory developments directly shape issue timelines and investor safeguards. Track how this affects upcoming filings on our IPO calendar.